On October 7, 2022 BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high value, traditionally undruggable targets, reported that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC and the company’s leading program TEAD inhibitors, have been accepted for poster presentation and discussion sessions at the 34th (ENA 2022) European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) (Free AACR Whitepaper) Symposium, which is being held October 26-28, 2022, in Barcelona (Press release, Bridgene Biosciences, OCT 7, 2022, View Source [SID1234621839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ENA 2022 will feature experts in cancer drug development and translational research who facilitate in-depth scientific discussions on the latest developments in targets and drugs from pre-clinical and phase I settings.

BridGene’s IMTAC enables the screening of small molecules against the whole proteome or selected targets in live cells to discover drug candidates for traditionally undruggable targets that are responsible for destructive diseases, including multiple types of cancer.

"We are delighted to announce that two abstracts have been accepted for presentation at ENA 2022. The abstracts feature research highlighting the capabilities of our IMTAC platform to identify novel therapeutic targets and novel compounds to drug ‘hard to drug’ targets," commented Ping Cao, Ph.D., Co-founder and CEO of BridGene Biosciences. "This symposium is internationally renowned for the quality of ground-breaking data presented. Our research being featured twice reflects the outstanding value of BridGene’s unique technology in drug discovery and development."

On October 7, 2022 At the 37th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts (United States), via in person/virtual attendance, Antengene reported that it will release data from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations (Press release, Antengene, OCT 7, 2022, View Source [SID1234621838]). As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC (Free SITC Whitepaper) Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 7, 2022 Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, reported that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets (Press release, Replimune, OCT 7, 2022, View Source [SID1234621835]). This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company’s registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This non-dilutive financing option provides Replimune with significant flexibility as we prepare for key RP1 skin franchise data catalysts and related commercial preparations of our novel tumor-directed oncolytic immunotherapies as well as the advancement of RP2/3 into Phase 2 studies," said Jean Franchi, Chief Financial Officer of Replimune. "Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it creates optionality in future capital formation and enables us to choose when, and to what extent, we access available funding in order to help manage future cost of capital and dilution."

"Hercules strives to align with some of the best and brightest companies in the life sciences industry to provide them with long-term capital commitments to help them achieve their ambitious goals. We are excited to collaborate with Replimune and their team ahead of numerous data, regulatory, and commercial milestones," said Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital.

The loan facility consists of up to six tranches, five of which can be drawn at Replimune’s option and each maturing in October 2027. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of certain milestones. An initial $30 million tranche was funded at closing with an additional $30 million available to be drawn at Replimune’s option prior to September 30, 2023. An additional $115 million is available subject to the Company’s achievement of specified performance milestones relating to clinical, regulatory, and commercial events. The final $25 million tranche is available for draw, at Replimune’s option and subject to Hercules consent during the interest-only period.

Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.

On October 7, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in October 2022 (Press release, Genprex, OCT 7, 2022, View Source [SID1234621834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Dawson James Securities Annual Small Cap Growth Conference

Event: Immuno-Oncology Summit

Event: BIO Europe

Event: LD Micro Main Event XV

Live Webcast Link: https://bit.ly/3EgC5af

For those interested in meeting Genprex management at LD Micro’s Main event, please request a meeting through LD Micro or reach out to Kalyn Dabbs at [email protected].

On October 7, 2022 Bristol Myers Squibb (NYSE:BMY) reported that it has changed the dial-in and replay information of its previously announced third quarter 2022 earnings conference call scheduled for Wednesday, October 26, 2022 (Press release, Bristol-Myers Squibb, OCT 7, 2022, View Source [SID1234621833]). Company executives will review financial results and address inquiries from investors and analysts during a conference call at 8:00 a.m. ET that same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new dial-in and replay information are as follows:

Investors and the general public are invited to listen to a live webcast of the call at View Source." target="_blank" title="View Source." rel="nofollow">View Source Investors and the public can also access the live webcast by dialing in the U.S. toll free 888-330-2388 or international +1 240-789-2707, confirmation code: 24168. Dial-in participants can register for the conference call here and once registration is complete, will not require operator assistance to connect. Materials related to the call will be available at View Source prior to the start of the conference call.

A replay of the webcast will be available on View Source approximately three hours after the conference call concludes. A replay of the conference call will be available beginning at 11:30 a.m. ET on October 26 through 11:30 a.m. ET on November 9, 2022, by dialing in the U.S. toll free 800-770-2030 or international +1 647-362-9199, confirmation code: 24168.